NCT02141490View on ClinicalTrials.gov

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 15, 2014

Primary Completion Date

November 20, 2018

Study Completion Date

November 20, 2018

Conditions
Prostate CancerBladder CancerKidney Cancer
Interventions
DRUG

Ferumoxytol

7.5mg/kg intravenous (IV) infusion

DIAGNOSTIC_TEST

Magnetic Resonance Imaging (MRI)

3 MRIs: pre-infusion, 24 and 48 hours post-infusion

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02141490 - Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers | Biotech Hunter | Biotech Hunter